Computational Insights into 1,4-Naphthoquinones as Allosteric MEK1 Inhibitors for Cancer Therapy
Current Pharmaceutical Design · Published 2026-07-13 · DOI 10.2174/0113816128449207260701111652
Authors (1)
Mohd Rehan
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Rehan, M. (2026). Computational Insights into 1,4-Naphthoquinones as Allosteric MEK1 Inhibitors for Cancer Therapy. Current Pharmaceutical Design. https://doi.org/10.2174/0113816128449207260701111652
Related articles
- Exploring the Potential of Dendrimers in Skin Drug Delivery: Applications andAdvances · Current Pharmaceutical Design · 2026 · Same journal
- Glycycoumarin Induces G2/M Cell Cycle Arrest and Apoptosis in Non-Small-Cell Lung Cancer Cells via Suppressing the PI3K/AKT/mTOR/HIF-1α Pathway · Current Pharmaceutical Design · 2026 · Same journal
- Discovery of Anti-Japanese Encephalitis Compounds: Based on Natural CompoundLibrary, Bioinformatics, Network Pharmacology and Experimental Validation · Current Pharmaceutical Design · 2026 · Same journal
- Combining Network Pharmacology, Machine Learning, Molecular Docking, andExperimental Validation to Explore the Mechanism of Danggui-Shaoyao-San intreating Rheumatoid arthritis · Current Pharmaceutical Design · 2026 · Same journal
- Receptor for Advanced Glycation End Products (RAGE) Ligand Axis as a Mediatorof Inflammation and Oxidative Stress in Cancer: Implications for CancerProgression and Therapeutic Targeting · Current Pharmaceutical Design · 2026 · Same journal
- Leveraging Untargeted Metabolomics and Molecular Dynamics SimulationUnraveling the Multi-Target Mechanism of Taohong Siwu Decoction againstPulmonary Hypertension · Current Pharmaceutical Design · 2026 · Same journal
- Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing MedicalDevice-Assisted Diagnosis · Current Pharmaceutical Design · 2026 · Same journal
- Polyphenols in Cancer Therapy: Recent Advances, Mechanistic Pathways, and Therapeutic Insights · Current Pharmaceutical Design · 2026 · Same journal
- Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, andRecent Innovations · Current Pharmaceutical Design · 2026 · Same journal
- Formulation, Characterization, and Preliminary In Vitro Evaluation of LetrozoleIncorporated Eudragit® RS 100 Nanoparticles Using HepG2 Cells · Current Pharmaceutical Design · 2026 · Same journal